Promoted Content
Promoted Content

Find FDA Investigational New Drug (IND) Submissions for Oncology in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CypCaps,Ifosfamide

            Therapeutic Area: Oncology Product Name: CypCaps

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 02, 2020

            Details:

            PharmaCyte has completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration (FDA) for its CypCaps™ final product, which will be used in the company’s planned clinical trial in locally advanced, inoperable pancreatic cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TAC-001

            Therapeutic Area: Oncology Product Name: TAC-001

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: venBio Partners

            Deal Size: $62.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing December 01, 2020

            Details:

            The Company plans to use the Series A funding to advance the discovery and development of immunotherapy candidates for multiple solid tumor maligniancies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BDTX-1535

            Therapeutic Area: Oncology Product Name: BDTX-1535

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 20, 2020

            Details:

            Black Diamond Therapeutics will Present pre-clinical data for BDTX-1535 and the biological rationale for a MasterKey approach to treating GBM patients whose tumors harbor allosteric oncogenic mutations in epidermal growth factor receptor.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Efineptakin alfa,Atezolizumab

            Therapeutic Area: Oncology Product Name: NT-I7

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Genentech

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            Details:

            This IND clearance allows NeoImmuneTech to initiate a multicenter Phase 2 study evaluating the anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab as a first-line (1L) treatment for NSCLC.